192 related articles for article (PubMed ID: 24750390)
1. Frequency of selected single nucleotide polymorphisms influencing the warfarin pharmacogenetics in Slovak population.
Krajčíová L; Petrovič R; Déžiová L; Chandoga J; Turčáni P
Eur J Haematol; 2014 Oct; 93(4):320-8. PubMed ID: 24750390
[TBL] [Abstract][Full Text] [Related]
2. Frequencies of polymorphisms in CYP2C9 and VKORC1 genes influencing warfarin metabolism in Slovak population: implication for clinical practice.
Krajciova L; Deziova L; Petrovic R; Luha J; Turcani P; Chandoga J
Bratisl Lek Listy; 2014; 115(9):563-8. PubMed ID: 25318916
[TBL] [Abstract][Full Text] [Related]
3. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.
Di Fusco D; Ciccacci C; Rufini S; Forte V; Novelli G; Borgiani P
Thromb Res; 2013 Jul; 132(1):123-6. PubMed ID: 23726967
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
[TBL] [Abstract][Full Text] [Related]
6. Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.
Fohner AE; Robinson R; Yracheta J; Dillard DA; Schilling B; Khan B; Hopkins S; Boyer B; Black J; Wiener H; Tiwari HK; Gordon A; Nickerson D; Tsai JM; Farin FM; Thornton TA; Rettie AE; Thummel KE
Pharmacogenet Genomics; 2015 Jul; 25(7):343-353. PubMed ID: 25946405
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
Farzamikia N; Sakhinia E; Afrasiabirad A
Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
[TBL] [Abstract][Full Text] [Related]
8. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
Giri AK; Khan NM; Grover S; Kaur I; Basu A; Tandon N; Scaria V; ; ; Kukreti R; Brahmachari SK; Bharadwaj D
Pharmacogenomics; 2014 Jul; 15(10):1337-54. PubMed ID: 25155935
[TBL] [Abstract][Full Text] [Related]
9. New genetic variant that might improve warfarin dose prediction in African Americans.
Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
[TBL] [Abstract][Full Text] [Related]
10. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
Ivashchenko D; Rusin I; Sychev D; Grachev A
Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
[TBL] [Abstract][Full Text] [Related]
11. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
14. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
15. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
[TBL] [Abstract][Full Text] [Related]
16. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
17. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
Scott SA; Edelmann L; Kornreich R; Desnick RJ
Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229
[TBL] [Abstract][Full Text] [Related]
18. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.
Botton MR; Bandinelli E; Rohde LE; Amon LC; Hutz MH
Br J Clin Pharmacol; 2011 Sep; 72(3):442-50. PubMed ID: 21320153
[TBL] [Abstract][Full Text] [Related]
19. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
20. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
